Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGNYIH)

Drug Name
Retigabine Drug Info
Synonyms
Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester
Indication
Disease Entry ICD 11 Status REF
Behcet disease 4A62 Approved [1]
Epilepsy 8A60-8A68 Withdrawn from market [2]
Therapeutic Class
Anticonvulsants
Cross-matching ID
PubChem CID
121892
ChEBI ID
CHEBI:68584
CAS Number
CAS 150812-12-7
TTD Drug ID
DMGNYIH
VARIDT Drug ID
DR00700
INTEDE Drug ID
DR1407
ACDINA Drug ID
D00263

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Approved Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Voltage-gated potassium channel Kv7.3 (KCNQ3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Linopirdine DM0ZOGX Cognitive impairment 6D71 Phase 3 [10]
ICA-105665 DMP925B Epilepsy 8A60-8A68 Phase 2 [11]
XEN1101 DMJVL57 Epilepsy 8A60-8A68 Phase 1 [2]
ICA-69673 DM1RZVI Pain MG30-MG3Z Preclinical [12]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [13]
PD-32577 DMBA15J Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv7 (KCNQ)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CNSB-001 DM2PEU5 Neuropathic pain 8E43.0 Phase 2 [15]
Flupirtine DMPBV9D Cancer related pain MG30 Phase 2 [16]
DMP-543 DMCNEOZ Parkinson disease 8A00.0 Discontinued in Phase 2 [17]
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [18]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [19]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [20]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [21]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [22]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [23]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [24]
Metronidazole DMTIVEN Abscess Approved [25]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [26]
Ethanol DMDRQZU Chronic pain MG30 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [28]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [29]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [30]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [31]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [32]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [33]
Estrone DM5T6US Acne vulgaris ED80 Approved [34]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [35]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [36]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A3 (UGT1A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [38]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [23]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [39]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [40]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [41]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [42]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [43]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [44]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [45]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [46]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [38]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [47]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [39]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [48]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [39]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [39]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [49]
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [39]
Haloperidol DM96SE0 Delirium Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [50]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [51]
Arsenic DMTL2Y1 N. A. N. A. Approved [52]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [53]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [54]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [55]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [56]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [57]
Sulforaphane DMQY3L0 Skin disease EA00-EM0Z Investigative [58]
BENZOYLENUREA DMY5O1U Discovery agent N.A. Investigative [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [60]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [61]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [62]
Gentamicin DMKINJO Bacteremia 1A73 Approved [61]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [61]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [61]
Arsenic DMTL2Y1 N. A. N. A. Approved [52]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [63]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [64]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [66]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [60]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [62]
Arsenic DMTL2Y1 N. A. N. A. Approved [52]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [67]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [56]
BENZOYLENUREA DMY5O1U Discovery agent N.A. Investigative [59]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [68]
Quinidine DMLPICK N. A. N. A. Approved [69]
Verapamil DMA7PEW Angina pectoris BA40 Approved [70]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [71]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [71]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [72]
Propranolol DM79NTF Angina pectoris BA40 Approved [73]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [74]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [75]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [71]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [76]
Methotrexate DM2TEOL Anterior urethra cancer Approved [66]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [77]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [78]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [62]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [79]
Arsenic DMTL2Y1 N. A. N. A. Approved [52]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [53]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [80]
Verapamil DMA7PEW Angina pectoris BA40 Approved [81]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [82]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [83]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [84]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [85]
Meloxicam DM2AR7L Arthritis FA20 Approved [86]
Quercetin DM3NC4M Obesity 5B81 Approved [87]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [77]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [78]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [88]
Luvox DMJKROX Anxiety disorder 6B00-6B0Z Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By SUMO-activating enzyme subunit 1 (SAE1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [90]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [91]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [92]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [93]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [94]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [95]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [53]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [96]
TAK-243 DM4GKV2 Solid tumour/cancer 2A00-2F9Z Phase 1 [97]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [56]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv7 (KCNQ) TTQ29KF NOUNIPROTAC Activator [2]
Voltage-gated potassium channel Kv7.3 (KCNQ3) TTIVDM3 KCNQ3_HUMAN Modulator [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [4]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [5]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [4]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [6]
Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2) OT3CXQJT KCNQ2_HUMAN Gene/Protein Processing [7]
Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3) OTXVBEED KCNQ3_HUMAN Drug Response [7]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) OT29B58J KCNQ4_HUMAN Gene/Protein Processing [8]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Gene/Protein Processing [6]
SUMO-activating enzyme subunit 1 (SAE1) OT18HFX5 SAE1_HUMAN Gene/Protein Processing [9]
Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C) OT6KFNMS CAC1C_HUMAN Gene/Protein Processing [6]

References

1 Clinical pipeline report, company report or official report of GlaxoSmithKline.
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3 The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
4 Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
5 N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006 Jun;55(6):711-21.
6 Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
7 The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine. J Biol Chem. 2016 Feb 5;291(6):2931-7. doi: 10.1074/jbc.M115.683185. Epub 2015 Dec 1.
8 The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
9 The SUMO-specific protease SENP2 plays an essential role in the regulation of Kv7.2 and Kv7.3 potassium channels. J Biol Chem. 2021 Oct;297(4):101183. doi: 10.1016/j.jbc.2021.101183. Epub 2021 Sep 10.
10 The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
11 New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
12 Voltage-gated Potassium Channels as Therapeutic Drug Targets
13 Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5.
14 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
15 The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72.
16 Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249.
17 KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus.Pharmacol Res.2011 Oct;64(4):397-409.
18 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
19 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
20 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
21 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
22 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
23 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
24 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
25 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
26 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
27 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
28 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
29 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
30 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
31 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
32 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
33 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
34 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
35 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
36 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
37 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
38 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
39 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
40 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
41 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
42 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
43 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
44 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
45 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
46 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
47 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
48 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
49 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
50 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
51 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
52 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
53 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
54 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
55 Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
56 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
57 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
58 Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
59 KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels. J Neurosci Methods. 2011 Aug 30;200(1):54-62. doi: 10.1016/j.jneumeth.2011.06.014. Epub 2011 Jun 23.
60 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
61 Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
62 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
63 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
64 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
65 Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
66 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
67 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
68 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
69 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
70 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
71 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
72 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
73 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
74 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
75 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
76 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
77 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
78 Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
79 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
80 Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
81 CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009 Aug;2(4):362-70. doi: 10.1161/CIRCGENETICS.109.857839. Epub 2009 Jun 3.
82 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
83 Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
84 Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
85 Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
86 Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
87 Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
88 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
89 Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. Europace. 2010 Feb;12(2):282-3. doi: 10.1093/europace/eup332. Epub 2009 Oct 29.
90 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
91 Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
92 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
93 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
94 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
95 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
96 Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
97 Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.